Cardiology 2013 (Full reference info)

Reference Type: Journal Article
Record Number: 566Author: Gornik, H. L., Gerhard-Herman, M. D., Misra, S., Mohler, E. R., 3rd, Zierler, R. E., Peripheral Vascular, Ultrasound, Physiological Testing Part, I. I. Testing for Venous Disease, Evaluation of Hemodialysis Access Technical, Panel and Appropriate Use Criteria Task, Force
Year: 2013
Title: ACCF/ACR/AIUM/ASE/IAC/SCAI/SCVS/SIR/SVM/SVS/SVU 2013 appropriate use criteria for peripheral vascular ultrasound and physiological testing part II: testing for venous disease and evaluation of hemodialysis access: a report of the american college of cardiology foundation appropriate use criteria task force
Journal: J Am Coll Cardiol
Volume: 62
Issue: 7
Pages: 649-65
Date: Aug 13
Short Title: ACCF/ACR/AIUM/ASE/IAC/SCAI/SCVS/SIR/SVM/SVS/SVU 2013 appropriate use criteria for peripheral vascular ultrasound and physiological testing part II: testing for venous disease and evaluation of hemodialysis access: a report of the american college of cardiology foundation appropriate use criteria task force
Alternate Journal: Journal of the American College of Cardiology
ISSN: 1558-3597 (Electronic)
0735-1097 (Linking)
DOI: 10.1016/j.jacc.2013.05.001
Accession Number: 23876422
Keywords: Advisory Committees/standards
American Heart Association
Cardiology/standards
Female
Guideline Adherence
Humans
Male
Peripheral Vascular Diseases/*ultrasonography
Practice Guidelines as Topic/*standards
Renal Dialysis/methods/standards
Societies, Medical/standards
Ultrasonography, Interventional/standards
United States
Vascular Access Devices/*standards
Venous Thrombosis/*ultrasonography
Notes: Gornik, Heather L
Gerhard-Herman, Marie D
Misra, Sanjay
Mohler, Emile R 3rd
Zierler, R Eugene
eng
R01 HL098967/HL/NHLBI NIH HHS/
Comparative Study
Review
2013/07/24 06:00
J Am Coll Cardiol. 2013 Aug 13;62(7):649-65. doi: 10.1016/j.jacc.2013.05.001. Epub 2013 Jul 19.
URL: http://www.ncbi.nlm.nih.gov/pubmed/23876422

Reference Type: Journal Article
Record Number: 703Author: Gorog, D. A. and Fuster, V.
Year: 2013
Title: Platelet function tests in clinical cardiology: unfulfilled expectations
Journal: J Am Coll Cardiol
Volume: 61
Issue: 21
Pages: 2115-29
Date: May 28
Short Title: Platelet function tests in clinical cardiology: unfulfilled expectations
Alternate Journal: Journal of the American College of Cardiology
ISSN: 1558-3597 (Electronic)
0735-1097 (Linking)
DOI: 10.1016/j.jacc.2012.11.080
Accession Number: 23541972
Keywords: Blood Platelets/*physiology
Cardiology/*methods
Humans
*Platelet Activation
Platelet Function Tests/methods
Thrombosis/*blood
Abstract: This review is a critical evaluation of publications in the past decade on the usefulness of platelet function tests (PFTs) in clinical cardiology, in aiding diagnosis, predicting risk, and monitoring therapy. The ideal PFT should: 1) detect baseline platelet hyperreactivity; 2) allow individualization of antiplatelet medication; 3) predict thrombotic risk; and 4) predict bleeding risk. The practicalities of clinical cardiology demand rapid, accurate, and reliable tests that are simple to operate at the bedside and available 24 h a day, 7 days a week. Point-of-care PFTs most widely evaluated clinically include PFA-100 and VerifyNow. None of these tests can reliably detect platelet hyperreactivity and thus identify a prothrombotic state. Identification of antiplatelet nonresponsiveness or hyporesponsiveness is highly test specific, and does not allow individualization of therapy. The power of PFTs in predicting thrombotic events for a given individual is variable and often modest, and alteration of antithrombotic treatment on the basis of the results of PFTs has not been shown to alter clinical outcome. PFTs in current mainstream use cannot reliably assess bleeding risk. These tests have been in use for over a decade, but the hopes raised by PFTs in clinical practice remain unfulfilled. Although physiologically relevant measurement of platelet function now is more important than ever, a critical reappraisal of available techniques in light of clinical requirements is needed. The use of native blood, global stimulus instead of individual agonists, contribution of thrombin generation by activated platelets to the test results, and establishment of a PFT therapeutic range for each antiplatelet drug should be considered and is discussed.
Notes: Gorog, Diana A
Fuster, Valentin
eng
Review
2013/04/02 06:00
J Am Coll Cardiol. 2013 May 28;61(21):2115-29. doi: 10.1016/j.jacc.2012.11.080. Epub 2013 Mar 26.
URL: http://www.ncbi.nlm.nih.gov/pubmed/23541972
Author Address: National Heart & Lung Institute, Imperial College, London, United Kingdom. d.gorog@imperial.ac.uk

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155